Page 40 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Benzodiazepine use and retention in OAT

Manag. 2023;19(5):433-443. 61. Engin E. GABA receptor subtypes and benzodiazepine use,
A
misuse, and abuse. Front Psychiatry. 2022;13:1060949.
doi: 10.5055/jom.0817
54. Barr AM, Panenka WJ, Honer WG, Khara S, Procyshyn RM. doi: 10.3389/fpsyt.2022.1060949
Excessive antipsychotic dosing in a Canadian outpatient 62. Jones AA, Cho LL, Kim DD, et al. Pain, opioid use, depressive
population. Psychiatr Serv. 2011;62(6):682-683. symptoms, and mortality in adults living in precarious
doi: 10.1176/ps.62.6.pss6206_0682a housing or homelessness: A longitudinal prospective study.
Pain. 2022;163:2213-2223.
55. Jones AA, Gicas KM, Seyedin S, et al. Associations of
substance use, psychosis, and mortality among people living doi: 10.1097/j.pain.0000000000002619
in precarious housing or homelessness: A longitudinal, 63. Zacny JP, Paice JA, Coalson DW. Separate and combined
community-based study in Vancouver, Canada. PLoS Med. psychopharmacological effects of alprazolam and
2020;17(7):e1003172. oxycodone in healthy volunteers. Drug Alcohol Depend.
doi: 10.1371/journal.pmed.1003172 2012;124(3):274-282.
56. Rintoul K, Song E, McLellan-Carich R, Schjelderup ENR, doi: 10.1016/j.drugalcdep.2012.01.023
Barr AM. A scoping review of psychiatric conditions 64. Jones CM, McCance-Katz EF. Co-occurring substance use
associated with chronic pain in the homeless and and mental disorders among adults with opioid use disorder.
marginally housed population. Front Pain Res (Lausanne). Drug Alcohol Depend. 2019;197:78-82.
2023;4:1020038.
doi: 10.1016/j.drugalcdep.2018.12.030
doi: 10.3389/fpain.2023.1020038
65. Day C. Benzodiazepines in combination with opioid pain
57. Troberg K, Bråbäck M, Isendahl P, Nilsson S, Dahlman D, relievers or alcohol: Greater risk of more serious ED visit
Håkansson A. Malmö Treatment Referral and Intervention outcomes. In: The CBHSQ Report. Rockville, MD: Substance
Study (MATRIS)-36-month follow-up on retention and Abuse and Mental Health Services Administration (US);
substance use among patients referred from needle exchange 2013. p. 1-9.
to opioid agonist treatment-The role of stimulant use at
baseline. J Subst Use Addict Treat. 2023;151:209036. 66. Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management,
and monitoring of combination opioid, benzodiazepines,
doi: 10.1016/j.josat.2023.209036 and/or alcohol use. Postgrad Med. 2013;125(4):115-130.
58. Mahu IT, Barrett SP, Conrod PJ, Bartel SJ, Stewart SH. doi: 10.3810/pgm.2013.07.2684
Different drugs come with different motives: Examining
motives for substance use among people who engage in 67. Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L. A meta-
polysubstance use undergoing methadone maintenance analysis of retention in methadone maintenance by dose and
therapy (MMT). Drug Alcohol Depend. 2021;229(Pt dosing strategy. Am J Drug Alcohol Abuse. 2009;35(1):28-33.
B):109133. doi: 10.1080/00952990802342899
doi: 10.1016/j.drugalcdep.2021.109133 68. Chambers LC, Hallowell BD, Zullo AR, et al. Buprenorphine
59. Lintzeris N, Nielsen S. Benzodiazepines, methadone and dose and time to discontinuation among patients with
buprenorphine: Interactions and clinical management. Am opioid use disorder in the era of fentanyl. JAMA Netw Open.
J Addict. 2010;19(1):59-72. 2023;6(9):e2334540.
doi: 10.1111/j.1521-0391.2009.00007.x doi: 10.1001/jamanetworkopen.2023.34540
60. Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, 69. Klimas J, Hamilton MA, Gorfinkel L, Adam A, Cullen W,
Busardò FP. Designer benzodiazepines: A review of Wood E. Retention in opioid agonist treatment: A rapid
toxicology and public health risks. Pharmaceuticals (Basel). review and meta-analysis comparing observational studies
2021;14(6):560. and randomized controlled trials. Syst Rev. 2021;10(1):216.
doi: 10.3390/ph14060560 doi: 10.1186/s13643-021-01764-9

Volume 8 Issue 3 (2025) 34 doi: 10.36922/itps.5151